Managing Biopharmaceutical Variability without Demanding Manufacturing Sameness through Lifecycle Evidence, Process Understanding, Change Control, and Product Evolution

Biopharmaceuticals are heterogeneous products whose molecular distributions may vary across batches, manufacturing sites, process states, storage periods, analytical platforms, and delivery configurations. Lifecycle assurance should therefore focus less on preserving historical manufacturing sameness and more on determining whether product evolution remains compatible with clinically relevant quality, safety, efficacy, exposure, and immunogenicity expectations. This article proposes a non-empiri